Find policies, billing codes, payers, states, and providers

CPT 0524U: sFlt‑1/PlGF Ratio Assay for Preeclampsia Diagnosis

CPT code 0524U designates a Proprietary Laboratory Analyses (PLA) test for the PreClaraTMRatio, quantifying the ratio of soluble fms–like tyrosine kinase-1 (sFlt–1) to placental growth factor (PlGF) via immunoassay. This CPT PLA code is specific to Thermo Fisher Scientific's PreClaraTMRatio assay and is used to aid in the diagnosis of preeclampsia by assessing biomarkers associated with placental vascular function. Nationally, the code matters because targeted biomarker assays for preeclampsia are increasingly used to stratify risk, inform clinical decision-making, and influence use of maternal-fetal monitoring resources.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, payer coverage context, common billing modifiers, and operational considerations for specimen type and typical site of service. The publication also summarizes expected content areas such as benchmark billing practices, relevant policy or coverage trends for proprietary lab tests, and clinical context for interpretation of an sFlt‑1/PlGF ratio. Data not available in the input will be identified where applicable.

Customize your policy alerts

Sign up for cpt 0524U policy alerts

Get alerted when payer policies referencing 0524U are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

CPT code 0524U is a Proprietary Laboratory Analyses (PLA) code assigned specifically to the PreClaraTMRatio (sFlt–1/PlGF) test from Thermo Fisher Scientific. The assay measures the ratio of soluble fms–like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) using an immunoassay on a serum or plasma sample to aid in the diagnosis of preeclampsia.

Service type: Proprietary laboratory diagnostic immunoassay

Typical site of service: Clinical laboratory or hospital laboratory

Data not available in the input.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

CPT 0524U: sFlt‑1/PlGF Ratio Assay for Preeclampsia Diagnosis

Customize your policy alerts

Sign up for cpt 0524U policy alerts

Get alerted when payer policies referencing 0524U are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service type: Proprietary laboratory diagnostic immunoassay

Typical site of service: Clinical laboratory or hospital laboratory

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A pregnant patient in the second or third trimester presents to an obstetric clinic or hospital with new-onset hypertension, proteinuria, or symptoms concerning for preeclampsia such as severe headache, visual changes, epigastric pain, or rapid edema. The ordering clinician (maternal-fetal medicine specialist, obstetrician-gynecologist, or labor and delivery physician) requests the PreClaraTMRatio (sFlt–1/PlGF) immunoassay to aid in the diagnostic evaluation and short-term risk stratification for preeclampsia.

The clinical workflow: the patient undergoes venipuncture for serum or plasma collection in an outpatient clinic, antepartum testing unit, emergency department, or inpatient labor and delivery unit. The specimen is labeled and sent to the performing laboratory (or the manufacturer's designated lab) for analysis using the proprietary Thermo Fisher Scientific assay. Results are reported to the ordering clinician and incorporated into clinical decision-making regarding monitoring intensity, timing of delivery, need for transfer to a higher level of maternal-fetal care, or outpatient follow-up. Billing for this proprietary laboratory analysis is reported using 0524U for the specific PreClaraTMRatio test.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting	Use when no additional modifier applies to the professional or technical components.
`26`	Professional component	Use when reporting only the professional component (interpretation) by the performing physician or laboratory director.
`TC`	Technical component	Use when reporting only the technical component (laboratory processing, equipment, and supplies).
`52`	Reduced services	Use when the laboratory performed a partially reduced service compared with the full assay (rare for PLA tests).
`53`	Discontinued procedure	Use if specimen collection or testing was started but discontinued for documented clinical reasons.
`22`	Increased procedural services	Use when work or resources for test performance/reporting substantially exceed typical; must be well documented.
`90`	Reference (outside) laboratory	Use when the test was performed by an outside reference laboratory and only the ordering facility bills for the test.

Taxonomy Code	Specialty	Notes
207Q00000X	Maternal and Fetal Medicine (Perinatology)	Specialists who manage high-risk pregnancies and commonly order preeclampsia risk testing.
207L00000X	Obstetrics & Gynecology	Obstetricians who evaluate and manage prenatal patients and order diagnostic testing.
208D00000X	Emergency Medicine	Emergency physicians may order the assay when pregnant patients present with acute symptoms suggestive of preeclampsia.
3336C0005X	Clinical Laboratory	Laboratory specialists who perform and validate the proprietary immunoassay.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`O14.03`	Mild pre-eclampsia, third trimester	Direct indication for sFlt-1/PlGF testing to aid diagnosis and risk stratification.
`O14.13`	Severe pre-eclampsia, third trimester	Used when assessing severity and short-term risk of progression; assay results inform monitoring/delivery decisions.
`O14.92`	Pre-eclampsia, unspecified, postpartum	Applied if preeclampsia is suspected or persistent after delivery; assay may be used in select postpartum evaluations.
`O13.9`	Gestational (pregnancy-induced) hypertension without significant proteinuria, unspecified trimester	sFlt-1/PlGF can help distinguish true preeclampsia from gestational hypertension.
`O99.89`	Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium	May be used for related hypertensive or vascular disorders in pregnancy where biomarker testing assists diagnosis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80048`	Basic metabolic panel	Used to evaluate renal function and electrolytes in patients with suspected preeclampsia; commonly ordered alongside sFlt-1/PlGF testing.
`82043`	Assay of estriol, unconjugated	Data not directly related; included as an example of pregnancy-related serum assays — not routinely paired with sFlt-1/PlGF.
`81025`	Urine pregnancy test, qualitative	Performed earlier in pregnancy; not typically concurrent but part of obstetric workflow.
`99000`	Handling and/or conveyance of specimen	May be used by some facilities for specimen handling fees when applicable to specialized reference testing.
`99070`	Supplies and materials (e.g., sterile trays)	Used when additional supplies are used in the collection or processing of specimens for specialized assays.

CPT 0001U: PreciseType HEA Multiplex Erythrocyte Antigen Assay

CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)

CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

CPT 0003U: Overa™ (OVA1 Next Generation) Ovarian Cancer Risk Assay

CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

CPT 0005U: ExosomeDx Prostate (IntelliScore) Urine Gene Expression Risk Test

CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication

CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing

Showing 1–10 of 536

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard reporting	Use when no additional modifier applies to the professional or technical components.
`26`	Professional component	Use when reporting only the professional component (interpretation) by the performing physician or laboratory director.
`TC`	Technical component	Use when reporting only the technical component (laboratory processing, equipment, and supplies).
`52`	Reduced services	Use when the laboratory performed a partially reduced service compared with the full assay (rare for PLA tests).
`53`	Discontinued procedure	Use if specimen collection or testing was started but discontinued for documented clinical reasons.
`22`	Increased procedural services	Use when work or resources for test performance/reporting substantially exceed typical; must be well documented.
`90`	Reference (outside) laboratory	Use when the test was performed by an outside reference laboratory and only the ordering facility bills for the test.

Taxonomy Code	Specialty	Notes
207Q00000X	Maternal and Fetal Medicine (Perinatology)	Specialists who manage high-risk pregnancies and commonly order preeclampsia risk testing.
207L00000X	Obstetrics & Gynecology	Obstetricians who evaluate and manage prenatal patients and order diagnostic testing.
208D00000X	Emergency Medicine	Emergency physicians may order the assay when pregnant patients present with acute symptoms suggestive of preeclampsia.
3336C0005X	Clinical Laboratory	Laboratory specialists who perform and validate the proprietary immunoassay.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`O14.03`	Mild pre-eclampsia, third trimester	Direct indication for sFlt-1/PlGF testing to aid diagnosis and risk stratification.
`O14.13`	Severe pre-eclampsia, third trimester	Used when assessing severity and short-term risk of progression; assay results inform monitoring/delivery decisions.
`O14.92`	Pre-eclampsia, unspecified, postpartum	Applied if preeclampsia is suspected or persistent after delivery; assay may be used in select postpartum evaluations.
`O13.9`	Gestational (pregnancy-induced) hypertension without significant proteinuria, unspecified trimester	sFlt-1/PlGF can help distinguish true preeclampsia from gestational hypertension.
`O99.89`	Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium	May be used for related hypertensive or vascular disorders in pregnancy where biomarker testing assists diagnosis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80048`	Basic metabolic panel	Used to evaluate renal function and electrolytes in patients with suspected preeclampsia; commonly ordered alongside sFlt-1/PlGF testing.
`82043`	Assay of estriol, unconjugated	Data not directly related; included as an example of pregnancy-related serum assays — not routinely paired with sFlt-1/PlGF.
`81025`	Urine pregnancy test, qualitative	Performed earlier in pregnancy; not typically concurrent but part of obstetric workflow.
`99000`	Handling and/or conveyance of specimen	May be used by some facilities for specimen handling fees when applicable to specialized reference testing.
`99070`	Supplies and materials (e.g., sterile trays)	Used when additional supplies are used in the collection or processing of specimens for specialized assays.

CPT 0001U: PreciseType HEA Multiplex Erythrocyte Antigen Assay

CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)

CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

CPT 0003U: Overa™ (OVA1 Next Generation) Ovarian Cancer Risk Assay

CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

CPT 0005U: ExosomeDx Prostate (IntelliScore) Urine Gene Expression Risk Test

CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication

CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

CPT 0011U: Cordant CORE™ Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcript Testing

Showing 1–10 of 536

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

CPT 0524U: sFlt‑1/PlGF Ratio Assay for Preeclampsia Diagnosis

Sign up for cpt 0524U policy alerts

Billing Code Overview

OpenPayer

CPT 0524U: sFlt‑1/PlGF Ratio Assay for Preeclampsia Diagnosis

Sign up for cpt 0524U policy alerts

Billing Code Overview

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References